Comparing Nihon Kohden (OTCMKTS:NHNKY) & enVVeno Medical (NASDAQ:NVNO)

enVVeno Medical (NASDAQ:NVNO) and Nihon Kohden (OTCMKTS:NHNKY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Valuation & Earnings

This table compares enVVeno Medical and Nihon Kohden”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$21.82 million	($1.08)	-0.36
Nihon Kohden	$1.48 billion	1.18	$93.05 million	$0.73	13.95

Nihon Kohden has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares enVVeno Medical and Nihon Kohden’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-61.45%	-56.88%
Nihon Kohden	7.78%	9.25%	6.60%

Insider & Institutional Ownership

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 0.1% of Nihon Kohden shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for enVVeno Medical and Nihon Kohden, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1	1	0	0	1.50
Nihon Kohden	0	0	0	0	0.00

Volatility & Risk

enVVeno Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, Nihon Kohden has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Summary

Nihon Kohden beats enVVeno Medical on 7 of the 11 factors compared between the two stocks.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

About Nihon Kohden

Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.